Advertisement

Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta

  • Masaki MatsushitaEmail author
  • Kenichi Mishima
  • Satoshi Yamashita
  • Nobuhiko Haga
  • Sayaka Fujiwara
  • Keiichi Ozono
  • Takuo Kubota
  • Taichi Kitaoka
  • Naoki Ishiguro
  • Hiroshi Kitoh
Original Article
  • 89 Downloads

Abstract

Osteogenesis imperfecta (OI) is a connective tissue disease with bone fragility. Several studies have indicated that physical function in adult OI was correlated to the disease severity, but there have been no reports delineating the impact of the fracture characteristics and disease-specific complications on health-related quality of life (HRQoL). The purpose of this study is to clarify the factors impacted on HRQoL in adult OI patients. We conducted a cross-sectional study between July 2016 and March 2018 and sent a questionnaire regarding HRQoL using Short Form-36 (SF-36) to the OI patients at the age of 20 years or older who had a medical history of the investigators’ institutions. The 40 patients completely answered the SF-36. Mental component summary and role/social component summary were unremarkable. Physical component summary (PCS) was significantly associated with z-score for height, teeth abnormality, and cardiopulmonary insufficiency (partial regression coefficient, 3.04, − 9.70, and − 11.35; p, < 0.001, 0.047, and 0.025, respectively). PCS was also significantly lower in the patients who had an initial fracture before the age of 2 years than those without occurrence of fractures until 2 years old (25.80 ± 17.15 versus 44.20 ± 16.54; p = 0.002), or those who had lower extremity fractures more than five times as compared with normal populations. Physical function was decreased in OI patients who had fractures before 2 years old, especially in lower extremity. Appropriate medical managements for cardiopulmonary insufficiency are required not only to maintain physical function but also to decrease mortality.

Keywords

Osteogenesis imperfecta SF-36 Quality of life Fracture Cardiopulmonary insufficiency 

Notes

Acknowledgements

This work was supported by Health Labour Sciences Research Grants, the Ministry of Health, Labour and Welfare, Japan.

Compliance with ethical standards

Conflict of interest

Each author certifies that he or she has no commercial associations that might pose a conflict of interest in connection with the submitted article.

Ethical approval

This study was approved by institutional review board of our institutions (reference number: 2015-0412).

Informed consent

We obtained informed consent from all participant patients.

Supplementary material

774_2019_1033_MOESM1_ESM.docx (28 kb)
Supplementary material 1 (DOCX 28 kb)
774_2019_1033_MOESM2_ESM.docx (28 kb)
Supplementary material 2 (DOCX 27 kb)

References

  1. 1.
    Andersen PE Jr, Hauge M (1989) Osteogenesis imperfecta: a genetic, radiological, and epidemiological study. Clin Genet 36:250–255CrossRefPubMedGoogle Scholar
  2. 2.
    Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101–116CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Van Dijk FS, Sillence DO (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A 164A:1470–1481.  https://doi.org/10.1002/ajmg.a.36545 CrossRefPubMedGoogle Scholar
  4. 4.
    Ben Amor IM, Roughley P, Glorieux FH, Rauch F (2013) Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res 28:2001–2007.  https://doi.org/10.1002/jbmr.1942 CrossRefPubMedGoogle Scholar
  5. 5.
    Chevrel G, Meunier PJ (2001) Osteogenesis imperfecta: lifelong management is imperative and feasible. Jt Bone Spine 68:125–129CrossRefGoogle Scholar
  6. 6.
    Paterson CR, McAllion S, Stellman JL (1984) Osteogenesis imperfecta after the menopause. N Engl J Med 310:1694–1696.  https://doi.org/10.1056/NEJM198406283102602 CrossRefPubMedGoogle Scholar
  7. 7.
    Forlino A, Marini JC (2016) Osteogenesis imperfecta. Lancet 387:1657–1671.  https://doi.org/10.1016/S0140-6736(15)00728-X CrossRefPubMedGoogle Scholar
  8. 8.
    Pillion JP, Shapiro J (2008) Audiological findings in osteogenesis imperfecta. J Am Acad Audiol 19:595–601CrossRefPubMedGoogle Scholar
  9. 9.
    Foster BL, Ramnitz MS, Gafni RI, Burke AB, Boyce AM, Lee JS, Wright JT, Akintoye SO, Somerman MJ, Collins MT (2014) Rare bone diseases and their dental, oral, and craniofacial manifestations. J Dent Res 93:7S–19S.  https://doi.org/10.1177/0022034514529150 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Radunovic Z, Wekre LL, Diep LM, Steine K (2011) Cardiovascular abnormalities in adults with osteogenesis imperfecta. Am Heart J 161:523–529.  https://doi.org/10.1016/j.ahj.2010.11.006 CrossRefPubMedGoogle Scholar
  11. 11.
    Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP (1993) Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 45:261–264.  https://doi.org/10.1002/ajmg.1320450223 CrossRefPubMedGoogle Scholar
  12. 12.
    McKiernan FE (2005) Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporos Int 16:1698–1702.  https://doi.org/10.1007/s00198-005-1905-5 CrossRefPubMedGoogle Scholar
  13. 13.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tosi LL, Oetgen ME, Floor MK, Huber MB, Kennelly AM, McCarter RJ, Rak MF, Simmonds BJ, Simpson MD, Tucker CA, McKiernan FE (2015) Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis 10:146.  https://doi.org/10.1186/s13023-015-0362-2 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Folkestad L, Hald JD, Ersboll AK, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K (2017) Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study. J Bone Miner Res 32:125–134.  https://doi.org/10.1002/jbmr.2920 CrossRefPubMedGoogle Scholar
  16. 16.
    Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B (1998) Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol 51:1045–1053CrossRefPubMedGoogle Scholar
  17. 17.
    Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K (1998) Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol 51:1037–1044CrossRefPubMedGoogle Scholar
  18. 18.
    Jain M, Tam A, Shapiro JR, Steiner RD, Smith PA et al (2019) Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genet Med 21:275–283.  https://doi.org/10.1038/s41436-018-0045-1 CrossRefPubMedGoogle Scholar
  19. 19.
    Hald JD, Folkestad L, Harslof T, Brixen K, Langdahl B (2017) Health-related quality of life in adults with osteogenesis imperfecta. Calcif Tissue Int 101:473–478.  https://doi.org/10.1007/s00223-017-0301-4 CrossRefPubMedGoogle Scholar
  20. 20.
    Malmgren B, Andersson K, Lindahl K, Kindmark A, Grigelioniene G, Zachariadis V, Dahllof G, Astrom E (2017) Tooth agenesis in osteogenesis imperfecta related to mutations in the collagen type I genes. Oral Dis 23:42–49.  https://doi.org/10.1111/odi.12568 CrossRefPubMedGoogle Scholar
  21. 21.
    Malmgren B, Norgren S (2002) Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol Scand 60:65–71CrossRefPubMedGoogle Scholar
  22. 22.
    Singer RB, Ogston SA, Paterson CR (2001) Mortality in various types of osteogenesis imperfecta. J Insur Med 33:216–220PubMedGoogle Scholar
  23. 23.
    McAllion SJ, Paterson CR (1996) Causes of death in osteogenesis imperfecta. J Clin Pathol 49:627–630CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K (2016) Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res 31:2159–2166.  https://doi.org/10.1002/jbmr.2895 CrossRefPubMedGoogle Scholar
  25. 25.
    Criscitiello MG, Ronan JA Jr, Besterman EM, Schoehwetter W (1965) Cardiovascular abnormalities in osteogenesis imperfecta. Circulation 31:255–262CrossRefPubMedGoogle Scholar
  26. 26.
    Stein D, Kloster FE (1977) Valvular heart disease in osteogenesis imperfecta. Am Heart J 94:637–641CrossRefPubMedGoogle Scholar
  27. 27.
    Lamanna A, Fayers T, Clarke S, Parsonage W (2013) Valvular and aortic diseases in osteogenesis imperfecta. Heart Lung Circ 22:801–810.  https://doi.org/10.1016/j.hlc.2013.05.640 CrossRefPubMedGoogle Scholar
  28. 28.
    White NJ, Winearls CG, Smith R (1983) Cardiovascular abnormalities in osteogenesis imperfecta. Am Heart J 106:1416–1420CrossRefPubMedGoogle Scholar
  29. 29.
    Kalath S, Tsipouras P, Silver FH (1987) Increased aortic root stiffness associated with osteogenesis imperfecta. Ann Biomed Eng 15:91–99CrossRefPubMedGoogle Scholar
  30. 30.
    Hortop J, Tsipouras P, Hanley JA, Maron BJ, Shapiro JR (1986) Cardiovascular involvement in osteogenesis imperfecta. Circulation 73:54–61CrossRefPubMedGoogle Scholar
  31. 31.
    Thiele F, Cohrs CM, Flor A, Lisse TS, Przemeck GK, Horsch M, Schrewe A, Gailus-Durner V, Ivandic B, Katus HA, Wurst W, Reisenberg C, Chaney H, Fuchs H, Hans W, Beckers J, Marini JC, Hrabe de Angelis M (2012) Cardiopulmonary dysfunction in the osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms. Hum Mol Genet 21:3535–3545.  https://doi.org/10.1093/hmg/dds183 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Scollan JP, Jauregui JJ, Jacobsen CM, Abzug JM (2017) The outcomes of nonelongating intramedullary fixation of the lower extremity for pediatric osteogenesis imperfecta patients: a meta-analysis. J Pediatr Orthop 37:e313–e316.  https://doi.org/10.1097/BPO.0000000000000970 CrossRefPubMedGoogle Scholar
  33. 33.
    Dwan K, Phillipi CA, Steiner RD, Basel D (2016) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 10:CD005088.  https://doi.org/10.1002/14651858.cd005088.pub4 CrossRefPubMedGoogle Scholar
  34. 34.
    Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977–986.  https://doi.org/10.1359/JBMR.050109 CrossRefPubMedGoogle Scholar
  35. 35.
    Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30:2150–2157.  https://doi.org/10.1002/jbmr.2567 CrossRefPubMedGoogle Scholar
  36. 36.
    Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Soderhall S, Ljunggren O, Astrom E (2016) Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate. Bone 87:11–18.  https://doi.org/10.1016/j.bone.2016.02.015 CrossRefPubMedGoogle Scholar
  37. 37.
    Bishop N, Adami S, Ahmed SF, Anton J, Arundel P et al (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382:1424–1432.  https://doi.org/10.1016/S0140-6736(13)61091-0 CrossRefPubMedGoogle Scholar
  38. 38.
    Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427–1431.  https://doi.org/10.1016/S0140-6736(04)16101-1 CrossRefPubMedGoogle Scholar
  39. 39.
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952.  https://doi.org/10.1056/NEJM199810013391402 CrossRefPubMedGoogle Scholar
  40. 40.
    Feehan AG, Zacharin MR, Lim AS, Simm PJ (2018) A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood. Bone 113:137–143.  https://doi.org/10.1016/j.bone.2018.05.021 CrossRefPubMedGoogle Scholar
  41. 41.
    Ablon J (2003) Personality and stereotype in osteogenesis imperfecta: behavioral phenotype or response to life’s hard challenges? Am J Med Genet A 122A:201–214.  https://doi.org/10.1002/ajmg.a.20257 CrossRefPubMedGoogle Scholar
  42. 42.
    Reite M, Davis K, Solomons C, Ott J (1972) Osteogenesis imperfecta: psychological function. Am J Psychiatry 128:1540–1546.  https://doi.org/10.1176/ajp.128.12.1540 CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Masaki Matsushita
    • 1
    Email author
  • Kenichi Mishima
    • 1
  • Satoshi Yamashita
    • 2
  • Nobuhiko Haga
    • 3
  • Sayaka Fujiwara
    • 3
  • Keiichi Ozono
    • 4
  • Takuo Kubota
    • 4
  • Taichi Kitaoka
    • 4
  • Naoki Ishiguro
    • 1
  • Hiroshi Kitoh
    • 1
    • 5
  1. 1.Department of Orthopaedic SurgeryNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Medical IT CenterNagoya University HospitalNagoyaJapan
  3. 3.Department of Rehabilitation Medicine, Graduate School of MedicineThe University of TokyoTokyoJapan
  4. 4.Department of PediatricsOsaka University Graduate School of MedicineOsakaJapan
  5. 5.Department of Orthopaedic SurgeryAichi Children’s Health and Medical CenterObuJapan

Personalised recommendations